arrow
M

Martin Grießhammer

johannes wesling medical centre minden
H指数:51
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial

鲁索利替尼一线治疗与最佳可用疗法在真性红细胞增多症患者中的比较:随机RuxoBEAT试验结果

2026-10-220
OAAI
The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

2025年德国ONKOPEDIA骨髓纤维化指南——德国血液学和肿瘤学学会(DGHO)MPN专家小组的建议

2026-08-150
OAAI
NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms

NLRP3诱导的全身性炎症控制JAK2V617F突变性骨髓增殖性肿瘤的发生发展

2025-11-260
OAAI
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy

肾疾病在应用Venetoclax为基础的低强度疗法治疗的初诊急性髓系白血病中的预后作用

2025-09-230
OAAI
Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry

骨髓增殖性肿瘤患者中应用抗血栓和细胞减少疗法减轻心房颤动相关并发症:来自GSG-MPN生物登记研究的启示

2025-03-170
OAAI
ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

ROP-ET:一项前瞻性III期试验,旨在研究罗普司坦alfa-2b在治疗治疗选择有限的真性红细胞增多症患者中的有效性和安全性

BLOOD
IF23.1
2024-11-050
OA
CSF3RT6181 Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)

CSF3RT6181被Calnexin稳定,并诱导未折叠蛋白反应(UPR)和ER-Phagy:一种慢性中性粒细胞白血病(CNL)中致癌性错误折叠CSF3R蛋白的促生存通路。

BLOOD
IF23.1
2024-11-050
PRE
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

分数: 德国MPN研究组 (gsg-mpn) 的骨髓纤维化和对JAK抑制剂治疗的耐药性或次优反应患者的Fedratinib和Nivolumab组合的II期研究方案

2024-07-053
OAAI
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
2024-03-044
OAAI
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
2024-01-0131
PRE
Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
LEUKEMIA
IF13.4
2023-02-242
OAAI
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

ruxolitinib在新诊断的真性红细胞增多症患者中的疗效和安全性: gsg-mpn研究组的RuxoBEAT临床试验的无效分析

2022-12-238
OAAI